-

Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education

  • Annual Grants Deepen Takeda’s Commitment to Improving Health Through Community-Based Programs
  • Takeda Publishes U.S. Community Impact Report Highlighting Progress toward a More Equitable Health Ecosystem

CAMBRIDGE, Mass.--(BUSINESS WIRE)--See the full release at Takeda.com

Contacts

Media Contact:
Takeda Media Relations
media_relations@takeda.com

Industry:

Takeda Pharmaceutical Company Limited

NYSE:TAK
Release Summary
Takeda has awarded grants to seven nonprofits that share its commitment to creating better health for people and a brighter future for the world.
Release Versions
English

Contacts

Media Contact:
Takeda Media Relations
media_relations@takeda.com

More News From Takeda Pharmaceutical Company Limited

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--FDA Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton as a Potential First-in-Class Therapy for Narcolepsy Type 1...

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment...

Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patients with IgA nephropathy through Week 96 – up to 18 months after the last mezagitamab dose.1 The result...
Back to Newsroom